{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mittal A"],"funding":["NCATS NIH HHS","NHLBI NIH HHS","National Cancer Institute","NCI NIH HHS"],"pagination":["10731"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8144401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Cutaneous squamous cell carcinomas (cSCC) are among the most commonly diagnosed malignancies, causing significant morbidity and mortality. Tumor-associated macrophage (TAM) expression of arginase is implicated in tumor progression, and therapeutic use of arginase inhibitors has been studied in various cancers. However, investigating potential cSCC immunotherapies including arginase inhibition in pre-clinical models is hampered by the lack of appropriate tumor models in immunocompetent mice. PDV is a cSCC cell line derived from chemical carcinogenesis of mouse keratinocytes. PDVC57 cells were derived from a PDV tumor in C57BL/6 (B6) mice. Unlike PDV, PDVC57 tumors grow consistently in B6 mice, and have increased TAMs, decreased dendritic and T cell intra-tumor infiltration. Arginase inhibit"],"journal":["Scientific reports"],"pubmed_title":["Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma."],"pmcid":["PMC8144401"],"funding_grant_id":["T35 HL007649","UL1 TR001863","1K08CA172580"],"pubmed_authors":["Wang M","Yanez D","Mittal A","Pizzurro G","Thakral D","Tracy E","Vidyarthi A","Colegio OR"],"additional_accession":[]},"is_claimable":false,"name":"Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma.","description":"Cutaneous squamous cell carcinomas (cSCC) are among the most commonly diagnosed malignancies, causing significant morbidity and mortality. Tumor-associated macrophage (TAM) expression of arginase is implicated in tumor progression, and therapeutic use of arginase inhibitors has been studied in various cancers. However, investigating potential cSCC immunotherapies including arginase inhibition in pre-clinical models is hampered by the lack of appropriate tumor models in immunocompetent mice. PDV is a cSCC cell line derived from chemical carcinogenesis of mouse keratinocytes. PDVC57 cells were derived from a PDV tumor in C57BL/6 (B6) mice. Unlike PDV, PDVC57 tumors grow consistently in B6 mice, and have increased TAMs, decreased dendritic and T cell intra-tumor infiltration. Arginase inhibit","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-19T15:37:03.28Z","creation":"2025-04-19T15:37:03.28Z"},"accession":"S-EPMC8144401","cross_references":{"pubmed":["34031449"],"doi":["10.1038/s41598-021-90200-y"]}}